Explore (New York, N.Y.) · 2026
Therapeutic potential of the polyherbal unani formulation in alcohol-induced fatty liver: A case report.
СтатьяКлинический случайНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
C Raziya Thaseen, A Shafiullah, Itrat Malik
Аннотация
BACKGROUND: Alcoholic fatty liver disease (AFLD) is characterized by excessive lipid accumulation in hepatocytes, which can progress to steatohepatitis, fibrosis, and cirrhosis if left untreated. Despite advances in modern medicine, effective targeted therapies remain limited. In Unani medicine, this condition is interpreted as Sū' Mizāj al-Kabid al-Ḥārr (morbid hot temperament of the liver), and treatment focuses on restoring hepatic balance through a polyherbal Unani formulation.
CASE PRESENTATION: A 50-year-old male with a long-standing history of chronic alcohol consumption presented with dyspepsia, nausea, and a sensation of heaviness in the right hypochondriac region. Ultrasonography revealed Grade I fatty liver with mild hepatomegaly. Laboratory investigations indicated elevated total cholesterol, LDL cholesterol, and mildly increased bilirubin levels. The patient was managed with the Unani formulation Arq Biranjasif (60 mL twice daily) for eight weeks.
RESULTS: After treatment, the patient reported marked improvement, with complete resolution of gastrointestinal symptoms. Follow-up biochemical tests showed reductions in total cholesterol, LDL cholesterol, and total bilirubin levels. Repeat ultrasonography demonstrated regression of hepatic steatosis and normalization of liver echotexture. No adverse effects were noted throughout the treatment period.
CONCLUSION: This case report suggests that Arq Biranjasif may offer therapeutic and hepatoprotective benefits in managing Grade I alcoholic fatty liver disease. Unani therapy, when combined with lifestyle modifications, could serve as a complementary approach to restoring hepatic function and preventing disease progression.
CASE PRESENTATION: A 50-year-old male with a long-standing history of chronic alcohol consumption presented with dyspepsia, nausea, and a sensation of heaviness in the right hypochondriac region. Ultrasonography revealed Grade I fatty liver with mild hepatomegaly. Laboratory investigations indicated elevated total cholesterol, LDL cholesterol, and mildly increased bilirubin levels. The patient was managed with the Unani formulation Arq Biranjasif (60 mL twice daily) for eight weeks.
RESULTS: After treatment, the patient reported marked improvement, with complete resolution of gastrointestinal symptoms. Follow-up biochemical tests showed reductions in total cholesterol, LDL cholesterol, and total bilirubin levels. Repeat ultrasonography demonstrated regression of hepatic steatosis and normalization of liver echotexture. No adverse effects were noted throughout the treatment period.
CONCLUSION: This case report suggests that Arq Biranjasif may offer therapeutic and hepatoprotective benefits in managing Grade I alcoholic fatty liver disease. Unani therapy, when combined with lifestyle modifications, could serve as a complementary approach to restoring hepatic function and preventing disease progression.